PsyBio Therapeutics Corp
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSYBF research report →
About the company
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company was founded on October 28, 2009 and is headquartered in Sunrise, FL.
- CEO
- Evan Levine
- IPO
- 2021
- Employees
- 118
- HQ
- Denver, CO, US
Price Chart
- Market Cap
- $1.27K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -867.29%
- ROIC
- 328.61%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,886,000 · 55.66%
- EPS
- $-0.04 · 58.00%
- Op Income
- $-4,337,711
- FCF YoY
- 50.52%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -825.95
- Avg Volume
- 5.30K
Get TickerSpark's AI analysis on PSYBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PSYBF coverage
Recent articles, reports, and earnings notes.
No research on PSYBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSYBF report →Similar companies
Peers in the same neighborhood.